This post is presented by our media partner Psychedelic News Wire
View the original article here.
Researchers from the Langone Center of Psychedelic Medicine at New York University and the Imperial College London’s Center for Psychedelic Research have published a study suggesting that small doses of MDMA could help reduce the uncomfortable effects of psilocybin and LSD. Psychedelics such as LSD and psilocybin (magic mushrooms) can produce feelings of euphoria and lead to life-changing insights, but they can also induce feelings of discomfort and anxiety in users.
Bad trips, as they are referred to, are a relatively common occurrence among psychedelic users and are characterized by symptoms such as extreme paranoia, sudden and extreme mood swings, negative thoughts and negative hallucinations. According to the study, taking a small MDMA dose alongside other psychedelics can reduce these negative effects while enhancing the positive effects of the psychedelic experience.
The small study involved polling 698 people who had recently consumed LSD or psilocybin. Twenty-seven of the participants said they used MDMA alongside either of the two psychedelics. Participants who took low MDMA doses with psilocybin or LSD reported “significantly lower levels” of challenging psychedelic experiences compared to participants who didn’t take MDMA. Furthermore, small MDMA doses seemed to increase the intensity of positive experiences but didn’t cause any discernible effect on mystical-type experiences and feelings such as compassion in people who used MDMA compared to those who didn’t.
The researchers published their findings in the peer-reviewed journal “Scientific Reports.”
The study noted that the findings point to MDMA as a potential buffer against some of the challenging aspects involved in psychedelic experiences while enhancing some positive experiences. The findings claim that the use of MDMA alongside LSD and psilocybin was associated with increased feelings of self-love, gratitude and compassion while significantly reducing the intensity of negative feelings like fear and grief.
Psychedelics have blown up in recent years, thanks to a flurry of scientific papers indicating their potential as alternative mental-health treatments. Studies have found that psychedelics such as psilocybin and LSD may be able to treat various mental-health conditions more effectively than conventional mental-health treatments, offering patients long-term relief with fewer side effects and minimal doses.
Although the psychedelic research field is still young, its findings have been so encouraging that psychedelic-assisted therapy is now predicted to revolutionize mental health. This most recent discovery could potentially improve treatment outcomes for psychedelic-assisted therapies that involve psilocybin and LSD by reducing the negative aspects of treatment while bolstering the positive aspects.
Needless to say, psychedelic drug development companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are likely to explore all possible hallucinogenic combinations that could deliver optimum clinical outcomes while posing the least number of risks to patients.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
